Global Non-Small Cell Lung Cancer Market 2025-2035

Description

List of Tables

Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report by Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others) by Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others) by Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), and by End-User Industry (Multispeciality Hospitals, and Cancer Research Centers) Forecast Period (2025-2035)

Industry Overview

Non-small cell lung cancer market was valued at $18.4 billion in 2024 and is projected to reach $35.8 billion by 2035, growing at a CAGR of 6.4% during the forecast period (2025-2035). The market growth is driven by factors like rising cancer prevalence due to smoking, air pollution, and an aging population. Key growth drivers include advances in diagnostics like CT scans and molecular testing, and the development of targeted therapies and immunotherapies for specific genetic mutations (e.g., EGFR, ALK). The market is also expanding due to increased demand for personalized treatment approaches and the overall growth of the oncology market.

Market Dynamics

Rising Incidence of Lung Cancer

The prevalence of NSCLC is increasing globally, particularly in regions with high smoking rates, urban air pollution, and industrial exposure. This rising incidence has intensified the demand for effective treatment options, advanced diagnostic tools, and personalized therapies. Early detection and targeted interventions are increasingly prioritized to improve patient outcomes, thereby driving market expansion.

Technological Advancements in Diagnostics and Therapy

The development of innovative therapies, including immunotherapy and precision-targeted drugs, has significantly improved survival rates. Advanced diagnostic modalities, such as high-resolution CT scans, PET-CT imaging, and minimally invasive biopsy techniques, are increasingly adopted. These technological innovations enhance treatment accuracy, reduce side effects, and increase overall treatment efficiency, fueling market growth.

Supportive Healthcare Policies and Investments

Government initiatives, rising healthcare budgets, and reimbursement policies for cancer treatment have created a favorable environment for NSCLC treatment adoption. Investments in oncology research, clinical trials, and awareness campaigns contribute to early diagnosis and better treatment outcomes, which further accelerate market growth across developed and emerging regions.

Market Segmentation

Based on the type, the market is segmented into adenocarcinomas, squamous cell carcinoma, large cell carcinomas, and others.
Based on the therapy, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery, and others.
Based on the diagnosis, the market is segmented into CT scan, X-rays, sputum cytology, bronchoscopy, laboratory tests, thoracoscopy, and others.
Based on the end-user industry, the market is segmented into multispeciality hospitals and cancer research centers.

Adenocarcinomas Largest Segment to Lead the Market

Among the NSCLC segments, adenocarcinomas are expected to lead the market with the largest share. Adenocarcinomas are the most common NSCLC subtype and are often diagnosed in non-smokers as well as smokers, increasing the eligible patient pool. Their heterogeneous nature has prompted the development of targeted therapies, immunotherapies, and combination treatment regimens, which are increasingly preferred in clinical practice.

Targeted Therapy: A Key Segment in Market Growth

Targeted therapy is identified as the key segment driving market growth in the NSCLC therapeutic landscape. Targeted therapies focus on specific genetic mutations, such as EGFR, ALK, and ROS1, providing personalized treatment options with higher efficacy and fewer side effects compared to conventional chemotherapy. The increasing availability of companion diagnostics enables precision medicine, ensuring the right treatment reaches the right patient. Collaborations between pharmaceutical companies and biotechnology firms are facilitating the development of next-generation inhibitors, combination therapies, and immuno-oncology treatments, thereby accelerating adoption. Additionally, government initiatives to enhance cancer screening programs and reimbursement coverage for novel therapies further bolster the uptake of targeted therapies. As a result, this segment is expected to maintain strong growth throughout the forecast period, significantly contributing to the overall market expansion.

Regional Outlook

The global non-small cell lung cancer market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Maintains Strong Market Position

North America holds a significant share of the global non-small cell lung cancer market. The US dominates the global NSCLC market with a major share. Factors contributing to this leadership include a high prevalence of lung cancer, sophisticated healthcare infrastructure, strong pharmaceutical R&D ecosystem, and early adoption of advanced diagnostics and targeted therapies. The presence of leading biopharmaceutical companies such as Pfizer, Merck, and Bristol-Myers Squibb, combined with extensive clinical trial networks, has facilitated the development and commercialization of innovative therapies. In addition, government programs like the National Cancer Institute (NCI) initiatives, Medicare and Medicaid reimbursement support, and patient awareness campaigns contribute to higher diagnosis and treatment rates.

The US market also benefits from high per capita healthcare expenditure, advanced hospital networks, and a robust regulatory framework supporting rapid approvals for oncology drugs. These factors collectively position the United States as a global hub for NSCLC treatment and research. Other North American countries, such as Canada, complement the market with supportive healthcare infrastructure and growing patient awareness. Meanwhile, emerging markets in the Asia-Pacific are witnessing rapid adoption due to increasing disease burden, yet the US remains the largest and most lucrative market globally.

Market Players Outlook

The major companies operating in the global non-small cell lung cancer market include AstraZeneca PLC, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In August 2025, World-first lung cancer vaccine trials are underway across seven countries, targeting non-small cell lung cancer (NSCLC). The BNT116 vaccine, developed by BioNTech, instructs the body to kill cancer cells and prevent their recurrence, aiming to improve survival rates in advanced forms of the disease.
In June 2025, Glenmark launched Tevimbra, a lung cancer drug in India, following approval from the Central Drugs Standard Control Organization (CDSCO). This innovative immuno-oncology therapy, developed by BeiGene, is indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line treatment for locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy. Tevimbra's active ingredient is tislelizumab-jsgr, a monoclonal antibody.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global non-small cell lung cancer market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024011

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Non-Small Cell Lung Cancer Market Sales Analysis - Type |Therapy| Diagnosis| Technology | End-User Industry ($ Million)
Non-Small Cell Lung Cancer Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Non-Small Cell Lung Cancer Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Non-Small Cell Lung Cancer Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Non-Small Cell Lung Cancer Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Non-Small Cell Lung Cancer Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Non-Small Cell Lung Cancer Market Revenue and Share by Manufacturers
Non-Small Cell Lung Cancer Treatment Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AstraZeneca PLC
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bristol-Myers Squibb
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Pfizer Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Merck & Co., Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Non-Small Cell Lung Cancer Market Sales Analysis By Type ($ Million)

5.1. Adenocarcinomas
5.2. Squamous Cell Carcinoma
5.3. Large Cell Carcinomas
5.4. Others

6. Global Non-Small Cell Lung Cancer Market Sales Analysis By Therapy ($ Million)

6.1. Chemotherapy
6.2. Targeted Therapy
6.3. Radiation Therapy
6.4. Surgery
6.5. Cryosurgery
6.6. Others

7. Global Non-Small Cell Lung Cancer Market Sales Analysis By Diagnosis ($ Million)

7.1. CT Scan
7.2. X-Rays
7.3. Sputum Cytology
7.4. Bronchoscopy
7.5. Laboratory Tests
7.6. Thoracoscopy
7.7. Others

8. Global Non-Small Cell Lung Cancer Market Sales Analysis By End-User Industry ($ Million)

8.1. Multispeciality Hospitals
8.2. Cancer Research Centers

9. Regional Analysis

9.1. North American Non-Small Cell Lung Cancer Market Sales Analysis - Type | Therapy| Diagnosis| Technology | End-User Industry ($ Million)
Macroeconomic Factors for North America
- 9.1.1. United States
- 9.1.2. Canada
9.2. European Non-Small Cell Lung Cancer Market Sales Analysis - Type | Therapy| Diagnosis| Technology | End-User Industry ($ Million)
Macroeconomic Factors for Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. France
- 9.2.6. Russia
- 9.2.7. Rest of Europe
9.3. Asia-Pacific Non-Small Cell Lung Cancer Market Sales Analysis - Type | Therapy| Diagnosis| Technology | End-User Industry ($ Million)
Macroeconomic Factors for Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.3.4. India
- 9.3.5. Australia & New Zealand
- 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 9.3.7. Rest of Asia-Pacific
9.4. Rest of the World Non-Small Cell Lung Cancer Market Sales Analysis - Type | Therapy| Diagnosis| Technology | End-User Industry ($ Million)
Macroeconomic Factors for the Rest of the World
- 9.4.1. Latin America
- 9.4.2. Middle East and Africa

10. Company Profiles

10.1. AbbVie
- 10.1.1. Quick Facts
- 10.1.2. Company Overview
- 10.1.3. Product Portfolio
- 10.1.4. Business Strategies
10.2. Amgen
- 10.2.1. Quick Facts
- 10.2.2. Company Overview
- 10.2.3. Product Portfolio
- 10.2.4. Business Strategies
10.3. AstraZeneca
- 10.3.1. Quick Facts
- 10.3.2. Company Overview
- 10.3.3. Product Portfolio
- 10.3.4. Business Strategies
10.4. BeiGene
- 10.4.1. Quick Facts
- 10.4.2. Company Overview
- 10.4.3. Product Portfolio
- 10.4.4. Business Strategies
10.5. Blueprint Medicines
- 10.5.1. Quick Facts
- 10.5.2. Company Overview
- 10.5.3. Product Portfolio
- 10.5.4. Business Strategies
10.6. Bristol Myers Squibb (BMS)
- 10.6.1. Quick Facts
- 10.6.2. Company Overview
- 10.6.3. Product Portfolio
- 10.6.4. Business Strategies
10.7. Celgene/BMS
- 10.7.1. Quick Facts
- 10.7.2. Company Overview
- 10.7.3. Product Portfolio
- 10.7.4. Business Strategies
10.8. Daiichi Sankyo
- 10.8.1. Quick Facts
- 10.8.2. Company Overview
- 10.8.3. Product Portfolio
- 10.8.4. Business Strategies
10.9. Eli Lilly
- 10.9.1. Quick Facts
- 10.9.2. Company Overview
- 10.9.3. Product Portfolio
- 10.9.4. Business Strategies
10.10. Incyte Corp.
- 10.10.1. Quick Facts
- 10.10.2. Company Overview
- 10.10.3. Product Portfolio
- 10.10.4. Business Strategies
10.11. Johnson & Johnson (Janssen)
- 10.11.1. Quick Facts
- 10.11.2. Company Overview
- 10.11.3. Product Portfolio
- 10.11.4. Business Strategies
10.12. Merck & Co.
- 10.12.1. Quick Facts
- 10.12.2. Company Overview
- 10.12.3. Product Portfolio
- 10.12.4. Business Strategies
10.13. Mirati Therapeutics
- 10.13.1. Quick Facts
- 10.13.2. Company Overview
- 10.13.3. Product Portfolio
- 10.13.4. Business Strategies
10.14. Novartis
- 10.14.1. Quick Facts
- 10.14.2. Company Overview
- 10.14.3. Product Portfolio
- 10.14.4. Business Strategies
10.15. Pfizer
- 10.15.1. Quick Facts
- 10.15.2. Company Overview
- 10.15.3. Product Portfolio
- 10.15.4. Business Strategies
10.16. Regeneron Pharmaceuticals
- 10.16.1. Quick Facts
- 10.16.2. Company Overview
- 10.16.3. Product Portfolio
- 10.16.4. Business Strategies
10.17. Roche/Genentech
- 10.17.1. Quick Facts
- 10.17.2. Company Overview
- 10.17.3. Product Portfolio
- 10.17.4. Business Strategies
10.18. Sanofi
- 10.18.1. Quick Facts
- 10.18.2. Company Overview
- 10.18.3. Product Portfolio
- 10.18.4. Business Strategies
10.19. Takeda Pharmaceuticals
- 10.19.1. Quick Facts
- 10.19.2. Company Overview
- 10.19.3. Product Portfolio
- 10.19.4. Business Strategies
10.20. Zai Lab
- 10.20.1. Quick Facts
- 10.20.2. Company Overview
- 10.20.3. Product Portfolio
- 10.20.4. Business Strategies